http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013144718-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
filingDate 2013-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7841c467426c0500fef1e582d0a718d
publicationDate 2013-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2013144718-A
titleOfInvention HERCEPTIN® adjuvant therapy
abstract A more effective medical treatment for a subject with non-metastatic breast cancer is provided. The present invention relates to results obtained in a clinical study of HERCEPTIN® supplementary use in human subjects with non-metastatic high-risk breast cancer. A method of adjunctive therapy, which binds to domain IV of HER2 bound by trastuzumab (HERCEPTIN®) after radical surgery for human subjects with non-metastatic HER2-positive breast cancer Administering an effective amount of the antibody and at least one chemotherapeutic agent to extend disease free survival (DFS) or overall survival (OS) in the subject, the DFS or OS Is evaluated approximately 2 to 5 years after the start of treatment. [Selection figure] None
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019529475-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018521064-A
priorityDate 2005-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002544238-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004110498-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003503365-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468136310

Total number of triples: 43.